1. Generics Bulletin

Pfizer’s Ruxience Rituximab Biosimilar Gets CHMP Nod

Positive Opinions Also Issued For Hybrids And Generics

 
• By Dave Wallace

Pfizer has received a positive opinion from the CHMP recommending granting a pan-European marketing authorization for its Ruxience rituximab biosimilar version of MabThera. At the same time, CHMP nods for hybrid medicines were received by SciPharm and Teva, while Mylan, Betapharm and Accord saw generics endorsed by the committee.

Europe_Night
The CHMP Has Recommended Granting Pfizer A Pan-European Marketing Authorization • Source: Shutterstock

Pfizer should be granted a pan-European marketing authorization for its Ruxience (rituximab) biosimilar, according to the European Medicines Agency’s Committee for Medicinal Products for Human Use.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products